AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06209697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: red clover
Description: Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
Study NCT06209697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: red clover
Description: Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
Study NCT05536648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial
Description: To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
Study NCT04979572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172
Description: * Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner
Study NCT04979572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner
Study NCT04870177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 infusion biweekly
Study NCT05334875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electroretinogram (ERG)
Description: Applying electrodes to assess retinal function
Study NCT05334875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual evoked potential (VEP)
Description: Applying electrodes to assess visual pathway function
Study NCT05448976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
Study NCT05448976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
Study NCT06728761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy urine test carried out during the intake visit on the day of the protocol
Description: Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.
Study NCT06148285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy
Study NCT06148285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy
Study NCT06148285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy
Study NCT06735040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: Before each treatment session, the borders of the thyroid gland were marked with ultrasound by an endocrinology specialist. Eight target points (superior, mediolateral, inferior borders of the right and left thyroid lobes, right and left side of the isthmus) were demarked with a surgical pen. PMBT was applied to the marked areas on the thyroid gland, which were approximately 1 cm apart from each other.
Study NCT04539431 — intervention group
Intervention type: GENETIC
Intervention: validation of new technologies
Description: Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
Study NCT06735040 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In the sham PMBT group, the probe was placed similarly to the treatment group. The screen of the laser device was active; however, the energy was set to 0 J and the power to 0 Mw, and the same procedures were also performed.
Study NCT05810116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levagen+
Description: Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
Study NCT05810116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Daily dose of 1-2 capsules (1 capsule containing 350mg)
Study NCT04202783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exosomes
Description: Focused ultrasound delivery of intravenously-infused exosomes
Study NCT06501261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM psychotherapy
Description: psychotherapy sessions
Study NCT05829187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin
Description: dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
Study NCT05829187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine
Description: piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
Study NCT06736964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Giomer
Description: based on Pre-reacted glass ionomer (PRG)
Study NCT06736964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Giomer
Description: based on Pre-reacted glass ionomer (PRG)
Study NCT06737822 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TPF or TPX Regimen (2# ICT) --> Surgery and Adjuvant Treatment
Description: TPF:~IINJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON DAY1 ONLY INJ. 5FU 750 MG/M2 IV THROUGH INFUSION PUMP OVER 24 HOURS D 1-4~Or~TPX Regimen INJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON D1 ONLY TAB. CAPECITABINE 850-1000MG/M2 TWICE A DAY 30 MINUTES AFTER MEALS FOR 14 DAYS IN A THREE WEEKLY CYCLE~Surgery and Adjuvant Treatment Patients with PR/CR or SD will go for surgical resection. Patients having PD but still localized and resectable will be offered surgical resection, other would undergo radical CTRT or Palliative Treatment.
Study NCT06737822 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Surgery and Adjuvant Treatment
Description: Wide Local Excision (WLE) with Comprehensive neck dissection and Adjuvant Treatment as per current standard Guidelines.
Study NCT06740149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (low dose)
Description: Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.
Study NCT05829187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
Study NCT05829187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momordica Charantia Extract
Description: Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
Study NCT05648656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA Nebulization
Description: Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
Study NCT05648656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NS Nebulization
Description: Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
Study NCT06740149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solvent of CG-BM1
Description: Administered intravenously, once a week for a total of 4 doses.
Study NCT06740149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (medium dose)
Description: Administered intravenously. For phase I: single infusion, 2.0×10\^6 cells /kg. For phase II: 2.0×10\^6 cells /kg once a week for a total of 4 times.
Study NCT04597372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
Study NCT04597372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
Study NCT06147973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Treatment (ABT)
Description: Participants will be provided with psycho-education, skill-builders, and other coaching to promote weight loss and healthy lifestyle changes.
Study NCT06147973 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education (HE) Comparison
Description: Participants will be provided with psych-education and resources to promote weight loss and healthy lifestyle changes. They will not be provided with directives.
Study NCT06166030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional blend (ImmuneRecov).
Description: Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
Study NCT05236127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soccer Heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
Study NCT05236127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
Study NCT05790304 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Camizestrant
Description: Camizestrant 75 mg tablets. Experimental drug.
Study NCT06071286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
Study NCT04756895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vancomycin dose adjustment using the Bayesian method
Description: This intervention is the experimental method. The AUC/MIC target is 400-600 mg\*hour/L.
Study NCT04756895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin dose adjustment using the trough level method
Description: This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.
Study NCT06345040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual-reality intervention
Description: For the experimental condition, participants will receive seven individual sessions of Virtual Reality Therapy conducted by a therapist trained in both eating disorder psychotherapy and virtual reality-based therapy, including avatar therapy. In the initial stage of therapy participants create a virtual avatar embodying their eating disorder voice. This enables the person to engage in real time face to face dialogue with the eating disorder voice. The main goal of the intervention is to encourage participants to stand up to the negative comments and commands made by the eating disorder voice and hereby increase their power and agency in the context of the eating disorder voice.
Study NCT06345040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU - specialized treatment
Description: The control condition encompasses treatment as usual comprising seven sessions of specialized treatment, such as individual or group psychotherapy and dietary guidance, provided by interdisciplinary health professionals.
Study NCT05628103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 flexibly dosed
Study NCT06203938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial infrared light stimulation
Description: Trancranial infrared light stimulation administered via light-emitting diodes
Study NCT06203938 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Identical to TILS, but with lights off
Study NCT06561490 — intervention group
Intervention type: RADIATION
Intervention: sonographic assesment of placental thickness and volume
Description: sonographic assesment of placental thickness and volume
Study NCT05244980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795
Description: TDM-105795 topical solution
Study NCT05244980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for TDM-105795 topical solution
Study NCT04541823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desﬂurane
Description: Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
Study NCT04541823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
Study NCT06361459 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stop smoking
Description: Sine fuma program is offered. nicotine is checked in urine
Study NCT06361459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop smoking
Description: Sine fuma program is offered. nicotine is checked in urine
Study NCT06070610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study NCT05710354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutridrink Compact Protein
Description: Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
Study NCT04789434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitor Tislelizumab maintenance therapy
Description: PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times
Study NCT05451264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood pressure measurement
Description: Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
Study NCT05451264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: blood pressure measurement
Description: Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
Study NCT06070610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Soft capsules
Study NCT06070610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Film-coated tablets
Study NCT05129176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: levofloxacin-tetracycline-containing quadruple regimens
Study NCT05733481 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries
Description: The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
Study NCT05763940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OmegaBoost
Description: An ultra-pure omega-3 fish oil supplement with no fishy aftertaste and no fish burps.~10x more omega-3 from fish oil than the leading omega-3 gummies. Gel bites have better absorption than ordinary, hard-to-swallow fish oil pills.
Study NCT05763940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nature Made (soft gel)
Description: A commercially-available omega-3 soft gel formula
Study NCT05763940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nature Made (gummy)
Description: A commercially-available omega-3 formula in gummy form
Study NCT05235256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral sphenopalatine ganglion block
Description: peripheral n block
Study NCT05235256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral greater occipital nerve block
Description: bilateral greater occipital nerve block
Study NCT05235256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine plus dexamethasone
Description: lidocaine plus dexamethasone
Study NCT05615961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)
Description: The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
Study NCT05615961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study NCT04993911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~* Walking forward~* Walking backward~* Side stepping~* Walk heel to toe~* Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position
Study NCT04993911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants of this group will receive only conventional therapy which will include; before beginning the program, each session will feature a 5-minute warm-up on a fitness bike or treadmill, followed by a 5-minute cool-down. Participants of this group will receive only conventional therapy which will include.~* CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artemisia afra tea infusions
Description: A. afra infusions of 5g/1litter of water, 3drinks a day, daily for 1week (7 days) (current recommendation).